New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment Pharmaceutical Investing
Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments Pharmaceutical Investing
Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022 Pharmaceutical Investing
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference Life Science Investing
AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® Annual Scientific Meeting Pharmaceutical Investing
